Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1188

1.

Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.

Fair WR, Betancourt JE.

Mol Urol. 2000 Fall;4(3):241-8;discussion 249-50.

PMID:
11062380
2.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
3.

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.

Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):15-23.

PMID:
15337535
4.
5.

The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.

Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y, Russo P, Soloway SM, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg CB, Heston WD, Reuter VE.

Urology. 1997 Mar;49(3A Suppl):46-55.

PMID:
9123736
7.

Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.

Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9.

PMID:
15667961
8.

Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.

Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD.

Urology. 2000 Aug 1;56(2):289-94.

PMID:
10925096
10.
11.

Role of radical prostatectomy in patients with prostate cancer of high Gleason score.

Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon D, Wood DP Jr, Pontes JE.

Prostate. 1999 Apr 1;39(1):60-6.

PMID:
10221268
12.

Neoadjuvant hormonal therapy in carcinoma of the prostate.

Lee HH, Warde P, Jewett MA.

BJU Int. 1999 Mar;83(4):438-48. Review.

PMID:
10210568
13.
14.

Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.

Debruyne FM, Witjes WP.

Mol Urol. 2000 Fall;4(3):251-6;discussion 257.

PMID:
11062381
16.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
17.
18.

Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.

Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. Epub 2005 May 31.

PMID:
15925452
19.

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.

PMID:
15050332

Supplemental Content

Support Center